Cullinan Therapeutics presented updated clinical data from its Phase 1 study of CLN-049 at the 67th ASH Annual Meeting.
CLN-049 demonstrated promising efficacy in a heavily pretreated all-comer population of patients with relapsed/refractory AML.
The novel FLT3xCD3 bispecific T cell engager showed encouraging response durability and multiple complete responses.
Promising Efficacy
CLN-049 demonstrated a 31% CR/CRh rate at the highest target dose tested, with a favorable safety profile.
Fast Track Designation
CLN-049 was recently granted Fast Track designation by the U.S. FDA, highlighting its potential to aid AML patients.
Novel Therapeutic Approach
CLN-049 targets FLT3, redirecting T cells to eliminate leukemic cells, showing early efficacy and durability benefits.
- CLN-049 offers hope for expanding treatment options for AML, especially for patients with poor prognosis like those with TP53-mutated AML.
- The therapy's targeting of FLT3, expressed in over 80% of AML patients, showcases its potential impact on AML treatment outcomes.
The clinical data presented by Cullinan Therapeutics at the ASH Meeting illustrate the potential of CLN-049 to revolutionize AML treatment and provide new hope for patients facing this devastating disease.